Real-World Outcomes of Adalimumab Treatment for Moderate and Severe Psoriasis in Korean Patients (RAPSODI Study)open access
- Authors
- Kim, D.H.; Son, S.W.; Jeong, K.-H.; Ahn, J.; Lee, E.-S.; Kim, I.-H.; Lee, U.H.; Park, H.-J.; Ko, J.Y.; Kim, B.-S.; Kim, J.J.; Rashid, J.; Kim, K.J.
- Issue Date
- Apr-2023
- Publisher
- 대한피부과학회
- Keywords
- Adalimumab; Health-related quality of life; Psoriasis
- Citation
- Annals of Dermatology, v.35, no.2, pp 107 - 115
- Pages
- 9
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- Annals of Dermatology
- Volume
- 35
- Number
- 2
- Start Page
- 107
- End Page
- 115
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/62991
- DOI
- 10.5021/ad.22.041
- ISSN
- 1013-9087
2005-3894
- Abstract
- Background: Psoriasis imposes a significant treatment burden on patients, particularly impacting well-being and quality of life (QoL). The psychosocial impact of psoriasis treatments remains unexplored in most patient populations. Objective: To assess the impact of adalimumab on health-related QoL (HRQoL) in Korean patients with psoriasis. Methods: This 24-week, multicenter, observational study, assessed HRQoL in Korean patients treated with adalimumab in a real-world setting. Patient-reported outcomes (PROs) including European Quality of Life-5 Dimension scale (EQ-5D), EQ-5D VAS, SF-36, and DLQI were evaluated at week 16 and 24, versus baseline. Patient satisfaction was assessed using TSQM. Results: Among 97 enrolled patients, 77 were assessed for treatment effectiveness. Most patients were male (52, 67.5%) and mean age was 45.4 years. Median baseline body surface area and Psoriasis Area and Severity Index (PASI) scores were 15.00 (range 4.00~80.00) and 12.40 (range 2.70~39.40), respectively. Statistically significant improvements in all PROs were observed between baseline and week 24. Mean EQ-5D score improved from 0.88 (standard deviation [SD], 0.14) at baseline to 0.91 (SD, 0.17) at week 24 (p=0.0067). The number of patients with changes in PASI 75, 90, or 100 from baseline to week 16 and 24 were 65 (84.4%), 17 (22.1%), and 1 (1.3%); and 64 (83.1%), 21 (27.3%), and 2 (2.6%), respectively. Overall treatment satisfaction was reported, including effectiveness and convenience. No unexpected safety findings were noted. Conclusion: Adalimumab improved QoL and was well-tolerated in Korean patients with moderate to severe psoriasis, as demonstrated in a real-world setting. Clinical trial registration number (clinicaltrials.gov: NCT03099083). Copyright © The Korean Dermatological Association and The Korean Society for Investigative Dermatology
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Dermatology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.